Skinvisible and Alto Pharmaceuticals (Alto) have entered into a license agreement for DermSafe, Skinvisible’s antimicrobial hand sanitiser lotion that recently completed clinical studies proving it kills the H1N1 virus.
As per the terms of the agreement, Alto is expected to pay Skinvisible an upfront license fee for the exclusive manufacturing and the commercial / professional use marketing rights for DermSafe in Canada. Skinvisible will also receive a royalty from product sales.
The company claims that DermSafe does not contain alcohol and is non-drying to the skin. The active ingredient in DermSafe is chlorhexidine gluconate, an ingredient approved by Health Canada under the Human Use Antiseptic Drugs Monograph.
The license agreement is the second DermSafe agreement signed by Skinvisible. The DermSafe licensee, Mayquest Pharmaceuticals has received approval to import DermSafe to Singapore and will commence commercial / professional sales in January 2010. Mayquest Pharmaceuticals has licensed the rights for DermSafe for five countries in Southeast Asia.
Terry Howlett, president and CEO of Skinvisible, said: “Alto’s sales team has extensive knowledge of the Canadian pharmaceutical market and is able to leverage their decades of experience and contacts to make DermSafe’s introduction into Canada a great success.
“They will initially be focused on the commercial sale of DermSafe to schools, the military, businesses and other commercial and professional establishments that are looking for a unique hand sanitiser made without alcohol.”